<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135083</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_3511</org_study_id>
    <nct_id>NCT00135083</nct_id>
  </id_info>
  <brief_title>Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus</brief_title>
  <official_title>One Versus Two Versus Three Daily Rapid-acting Insulin Injections of APIDRA (Insulin Glulisine) as add-on to Lantus® and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-label Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show the non-inferiority of insulin glulisine administered&#xD;
      with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c&#xD;
      (HbA1c), from baseline to study week 24.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To show non-inferiority between treatment groups (insulin glargine plus insulin glulisine administered once a day, twice a day, or 3 times a day) in the change in glycemic control as measured by hemoglobin A1C.</measure>
    <time_frame>From baseline to study week 24.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily:&#xD;
Insulin glulisine Dosing: Supper, Lunch, Breakfast&#xD;
Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily:&#xD;
Insulin glulisine Dosing: Supper &amp; Lunch, Lunch &amp; Breakfast, Breakfast &amp; Supper&#xD;
Monitoring Needed at: Bedtime &amp; Pre-Supper, Pre-Supper &amp; Pre-Lunch, Pre-Lunch &amp; Bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily:&#xD;
Insulin glulisine Dosing: Supper, Lunch, Breakfast&#xD;
Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glulisine</intervention_name>
    <description>Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.&#xD;
Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.&#xD;
Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects with type 2 diabetes mellitus who have been using a stable combination oral&#xD;
        antidiabetic therapy of 2 or 3 agents in different therapeutic classes for on at least 3&#xD;
        months will be enrolled in this study.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects 18 to 79 years of age with a diagnosis of type 2 diabetes&#xD;
             mellitus for at least 6 months&#xD;
&#xD;
          -  Current treatment with a stable dose of 2 oral antidiabetic agents. The oral agents&#xD;
             must be in 2 or 3 of the following 3 different classes:&#xD;
&#xD;
               -  Sulfonylurea: dosage greater than or equal to, one-half the maximum recommended&#xD;
                  dosage (eg, glimepiride &gt;/= 4 mg; glipizide, including gastrointestinal&#xD;
                  therapeutic system [GITS], &gt;/= 10 mg; glyburide &gt;/= 10 mg; Glynase® &gt;/=3 mg). The&#xD;
                  dosage must have been stable for at least 3 months prior to screening.&#xD;
&#xD;
               -  Biguanide: metformin dosage ≥ 1000 mg daily, including Glucophage XR®. The dosage&#xD;
                  must have been stable for at least 3 months prior to screening.&#xD;
&#xD;
               -  Thiazolidinedione (TZD): pioglitazone &gt;/= 15 mg or rosiglitazone &gt;/= 24 mg. The&#xD;
                  subject must have been using the same thiazolidinedione for at least 6 months,and&#xD;
                  the dosage must have been stable for at least 3 months prior to screening.&#xD;
&#xD;
          -  HbA1c &gt;/= 8.0%&#xD;
&#xD;
          -  Fasting C-peptide concentration &gt; 0.27 nmol/L&#xD;
&#xD;
          -  Able and willing to perform self-monitoring of blood glucose (SMBG) up to 4 times a&#xD;
             day&#xD;
&#xD;
          -  Able and willing to adhere to, and be compliant with, the study protocol&#xD;
&#xD;
          -  Able to read English or Spanish at the sixth-grade level in order to complete the&#xD;
             subject reported outcomes component of the study&#xD;
&#xD;
          -  Signed informed consent and Health Insurance Portability and Accountability Act&#xD;
             (HIPAA) authorization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin use within the previous year&#xD;
&#xD;
          -  History of hypoglycemia unawareness&#xD;
&#xD;
          -  Acute or chronic, or history of, metabolic acidosis, including diabetic ketoacidosis&#xD;
&#xD;
          -  Impaired renal function as shown by, but not limited to, serum creatinine ≥ 3mg/dL.&#xD;
             For subjects taking metformin, serum creatinine &gt;/= 1.5 mg/dL for males, or &gt;/= 1.4&#xD;
             mg/dL for females.&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels&#xD;
             greater than 2.5 times the upper limit of normal (ULN)&#xD;
&#xD;
          -  Clinically significant peripheral edema if subject is using a TZD&#xD;
&#xD;
          -  History of stroke, myocardial infarction, coronary artery bypass graft, percutaneous&#xD;
             transluminal coronary angioplasty, or angina pectoris, within the past 12 months&#xD;
&#xD;
          -  History of, or current, congestive heart failure (New York Heart Association [NYHA]&#xD;
             III-IV) requiring pharmacologic treatment&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  Any malignancy within the past 5 years, with the exception of adequately treated basal&#xD;
             or squamous cell carcinoma or adequately treated cervical carcinoma in situ&#xD;
&#xD;
          -  Current substance addiction or alcohol abuse or history of substance or alcohol abuse,&#xD;
             within the past 2 years&#xD;
&#xD;
          -  Any clinically significant renal disease (other than proteinuria) or hepatic disease&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Dementia or mental condition rendering the subject unable to understand the nature,&#xD;
             scope, and possible consequences of the study&#xD;
&#xD;
          -  Impaired dexterity or vision rendering the subject unable to administer injections&#xD;
&#xD;
          -  Known hypersensitivity to insulin glargine or insulin glulisine or any of the&#xD;
             components of Lantus or Apidra&#xD;
&#xD;
          -  Any disease or condition (including abuse of illicit drugs, prescription medications,&#xD;
             or alcohol) that, in the opinion of the investigator or sponsor, may interfere with&#xD;
             the completion of the study&#xD;
&#xD;
          -  Unlikely to comply with the protocol, eg, uncooperative attitude, inability to return&#xD;
             for follow-up visits, or unlikely to complete the study&#xD;
&#xD;
          -  Subject is the investigator or any sub-investigator, research assistant, pharmacist,&#xD;
             study coordinator, other staff, or relative thereof, directly involved in the conduct&#xD;
             of the protocol&#xD;
&#xD;
          -  No subject will be allowed to enroll in this study more than once.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Barch, B.S.</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>August 23, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin glulisine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

